Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli-Reference-Cited by-同舟云学术

Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli

Published:2012-06-04 Issue:10 Volume:67 Page:2424-2428
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:Journal of Antimicrobial Chemotherapy

Author:

Lampri N.,Galani I.,Poulakou G.,Katsarolis I.,Petrikkos G.,Giamarellou H.,Souli M.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/67/10/2424/2142653/dks215.pdf

Reference13 articles.

1. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited

2. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

3. Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment

4. Does the Activity of the Combination of Imipenem and Colistin In Vitro Exceed the Problem of Resistance in Metallo-β-Lactamase-Producing Klebsiella pneumoniae Isolates?

5. Activity of mecillinam against AmpC -lactamase-producing Escherichia coli

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens;Open Forum Infectious Diseases;2024-05-24

2. Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI);Trials;2023-09-02

3. Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam;Microbiology Spectrum;2023-04-13

4. Pivmecillinam with Amoxicillin/Clavulanic acid as Step Down Oral Therapy in Febrile Urinary Tract Infections Caused by ESBL-producing Enterobacterales (PACUTI);2023-02-17

5. Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae;Antibiotics;2022-09-20